J&J Begins Human Trials Of Experimental Ebola Vaccine

Bloomberg News: J&J Injects First Volunteer in Race to Make Ebola Vaccine
“Johnson & Johnson (JNJ) started a trial of its experimental Ebola vaccine in the U.K. and said it will produce two million courses of the shot this year…” (Bennett, 1/6).

Reuters: J&J, Bavarian Nordic start clinical tests in Ebola vaccine race
“…The initiation of the Phase I study in Britain, which had been expected about now, marks further progress in the race to develop a vaccine against a disease that has killed more than 8,000 people in West Africa since last year…” (Hirschler, 1/6).

Wall Street Journal: J&J Begins Human Testing of Ebola-Virus Vaccine
“…J&J said some volunteers have already received their initial vaccine dose, and enrollment is expected to wrap up by the end of the month. The early-stage clinical trial is being led by the University of Oxford’s pediatrics department…” (Dulaney, 1/6).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.